Upgrade to SI Premium - Free Trial

Eli Lilly & Co. (LLY) Reports Mirikizumab Met Primary Endpoint & Key Secondary Endpoints in Phase 2 Study, Including Reductions of Gastrointestinal Lesions

May 21, 2019 1:21 PM
In an oral presentation from the Digestive Disease Week medical conference in San Diego, California today, Eli Lilly and Company ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Corporate News FDA Management Comments

Next Articles